Iceland· IS-EU/1/24/1798/001
Lytenava
A bevacizumab product containing bevacizumabum inn, registered in Iceland by Outlook Therapeutics NL B.V.. The same ATC class is registered in 9 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Bevacizumab is registered in 9 of 19 countries.
Countries holding a registration under ATC S01LA08 (bevacizumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 5 of them publish a price we can compare per daily dose
Bevacizumab · ATC S01LA08
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Bevacizumabum INN
- Manufacturer
- Outlook Therapeutics NL B.V.
- Country
- Iceland (IS)
- ATC code
- S01LA08
- ATC class
- Bevacizumab
- Defined daily dose
- 0.036 DE, IVT
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Bevacizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumLytenava 25 mg/mlOutlook Therapeutics NL
- CzechiaLYTENAVAOutlook Therapeutics NL B.V., Amsterdam
- IrelandLytenava 25 mg/mL solution for injectionOutlook Therapeutics NL B.V.
- NetherlandsLytenava 25 mg/ml oplossing voor injectieOutlook Therapeutics NL B.V.
- PolandLytenavaOutlook Therapeutics Limited
- SwedenLytenava 25 mg/ml Injektionsvätska, lösningOutlook Therapeutics NL B.V.
- United KingdomAbevmy 100mg/4ml concentrate for solution for infusion vialsBiocon Biologics Ireland Ltd
- United StatesALYMSYSAmneal Pharmaceuticals LLC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Oyavas
- Liechtenstein · Abevmy, Alymsys
- Norway · Abevmy, Alymsys
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1bb69771-ccce-4c11-a3a1-4cd234b9adda GET /v1/drugs/1bb69771-ccce-4c11-a3a1-4cd234b9adda?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn",
"source": "lyfjastofnun",
"atc_raw": "S01LA08",
"marketed": false,
"strength": "25 mg/ml",
"ma_number": "EU/1/24/1798/001",
"substance": "Bevacizumabum INN",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "45439"
}See everything about bevacizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.